Predictive factors of hyperuricemia in diabetics Type 2: About 168 cases

Fennoun, Halima; Aziz, S. El; Bensbaa, S.; Chadli, Asma

doi:10.1530/endoabs.56.ep62

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, we found that patients with high SUA levels had a significantly higher frequency of HTN and CKD. The current study agreed with Fennon and colleagues who observed that the frequency of hypertension, older age, smoking, higher body mass index, and poor glycemic control were higher among patients with hyperuricemia [13].…”

Section: Discussionsupporting

confidence: 93%

“…In our study, we found that the majority (53.1%) of patients with high SUA were males and the majority (69.6%) of patients with normal SUA were females with significant difference (p < 0.001). This finding was consistent with a previous study [13]. In contrast to this finding, Rafiullah et al reported that high SUA was found in 13% of studied males and 18.5% of studied females [6].…”

Section: Discussionsupporting

confidence: 93%

“…Ma and colleagues found that out of 198 patients with T2DM, 15.6% of patients had high SUA [11]. Also, 26.3% with T2DM had high SUA [13]. This difference may be contributed to a small sample size, different studied populations, and selection bias.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The association of serum uric acid level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status

Argoons,

Mahmoud,

Madkour

2024

Egypt J Intern Med

View full text Add to dashboard Cite

Background The importance of uric acid has been increasingly appreciated because of its association with the development of diabetes mellitus and related diseases, and with the increasing incidence of diabetes, studying the impact of hyperuricemia in patients with diabetes type 2 is necessary. So we aimed to measure serum uric acid (SUA) levels in patients with diabetes type 2 and to assess the relation between the estimated glomerular filtration rate (eGFR) and the SUA in patients with type 2 diabetes (T2DM). Subjects and methods This study is a cross-sectional conducted on 142 adult patients who attended the Outpatients Diabetes Clinic and Endocrinology Center in the Department of Internal Medicine, Assiut University Hospitals, in the period from the 1st of November 2021 up to October 2022. We measured serum uric acid level, serum creatinine, cholesterol, low- and high-density lipoproteins, triglycerides, and eGFR. Results Overall, 142 patients were enrolled in the study; all patients had type 2 diabetes. The mean age of the participants was 61.08 ± 9.73 years. Based on SUA level, 46 (32.4%) patients had normal SUA and 96 (67.6%) patients had high SUA. Sixty-nine (48.6%) patients had normal eGFR and 73 (51.4%) patients had reduced eGFR. We found that serum uric acid had a positive significant correlation with the number of metabolic syndrome criteria, cholesterol, low-density lipoproteins, and triglycerides. Meanwhile, it had a negative significant correlation with eGFR and high-density lipoproteins. Conclusion Serum uric acid was strongly associated with metabolic syndrome components and reduced eGFR in patients with T2DM.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

The association of serum uric acid level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status

Argoons,

Mahmoud,

Madkour

2024

Egypt J Intern Med

View full text Add to dashboard Cite

show abstract

“…Serum Uric Acid (SUA) levels tend to be higher in individuals with T2DM and prediabetes compared to those without these conditions [ 4 ]. Hyperuricemia is influenced by various factors commonly found in diabetic patients, including increased body weight, waist circumference, dyslipidemia, sedentary lifestyle, hypertension, and insulin resistance [ 5 , 6 ]. Studies indicated that increased SUA levels were positively associated with gout, kidney diseases, atherosclerosis, hypertension, stroke, and cardiovascular diseases [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

You,

Zhao,

Chen

et al. 2023

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Serum uric acid levels are higher in patients with type 2 diabetes and prediabetes compared to healthy individuals, and hyperuricemia causes a significant rate of complications and mortality through heart and kidney diseases. Accordingly, the present systematic review and meta-analysis aimed to investigate the effect of empagliflozin on serum uric acid levels. Materials and methods Electronic databases, including PubMed, Scopus, Web of Science, Cochrane, and Google Scholar, were used to search papers until May 22, 2023. Data analysis was conducted by STATA Version 14, and P-value < 0.05 were considered statistically significant. Results The results obtained from the combination of 12 studies with 7801 samples of diabetic patients indicated that in the empagliflozin group, the serum uric acid levels of the patients decreased ([standardized mean difference (SMD): − 1.97 (95%CI − 3.39, − 0.55)], Systolic blood pressure (SBP) [SMD: − 2.62 (95%CI − 3.87, − 1.37)] and diastolic blood pressure (DBP) [SMD: − 0.49 (95%CI − 0.68, − 0.29)]). On the other side, empagliflozin treatment did not affect the patients’ HbA1c levels ([SMD: − 2.85 (95%CI − 6.14, 0.45)], eGFR [SMD: 0.78 (95%CI − 0.63, 2.18)], creatinine [SMD:0.11 (95%CI − 0.10, 0.31)], LDL [SMD: 0.14 (95%CI − 0.43, 0.71)], and HDL [SMD:1.38 (95%CI − 0.22, 2.99)]). Compared with the placebo, empagliflozin was more effective in reducing the uric acid levels ([SMD: − 1.34 (95%CI − 2.05, − 0.63)], SBP [SMD: − 2.11 (95%CI − 3.89, − 0.33)], and HbA1c [SMD: − 1.04 (95%CI − 1.95, − 0.13)]). Moreover, compared with sitagliptin also, empagliflozin was more effective in reducing uric acid levels ([SMD: − 1 (95%CI − 1.78, − 0.22)], and creatinine [SMD: − 1.60 (95%CI − 2.28, − 0.92)]) and increasing eGFR levels [SMD: 0.99 (95%CI: 0.37, 1.62)] of the patients. Compared with dapagliflozin also, empagliflozin caused a reduction in eGFR level [SMD: − 0.45 (95%CI − 0.82, − 0.08)]. Conclusion Empagliflozin treatment was effective in controlling diabetic patients’ hyperuricemia and hypertension.

show abstract

“…Uric acid (UA) is a biomarker that is associated with MetS and has been proposed as a novel biomarker in the identification of MetS [9]. Yet, study authors report UA as simply being associated with MetS but not necessarily a cause of MetS and other diseases [9,10]. UA is associated with purine degradation and is formed in the liver with some additional production by the intestines, eventually being excreted by the kidneys.…”

Section: Introductionmentioning

confidence: 99%

Uric Acid as a Novel Component of Metabolic Syndrome

Rodney G,

Kathleen A,

Luke T

2023

Int J Clin Cardiol

View full text Add to dashboard Cite

Objective: Uric continues to be explored as a novel risk factor for Metabolic Syndrome. The purpose of our study was to identify risk factors that are associated with hyperuricemia and to better understand if uric acid might serve as a useful component of metabolic syndrome. Methods:A cross-sectional data analysis was conducted using the 2013-2018 NHANES datasets. Sample weights were assigned by NHANES researchers to each participant allowing researchers to generalize results to all non-institutionalized US civilians. The analysis included 6,432 individuals, which were representative of 94,729,059 US citizens. Results:We demonstrated that the risk factors that had a statistically significant relationship with UA value were fasting glucose, triglycerides, systolic BP, and waist circumference. Fasting blood glucose had an inverse relationship with UA level, indicating that for every 1-point increase in fasting blood glucose, uric acid level decreased slightly. The most adjusted model reports HDL also demonstrated an inverse relationship with UA but this relationship was attenuated after controlling for potential confounders. Triglyceride level, systolic BP, and WC had direct relationships with UA level, indicating that as each risk factor increased, UA level also increased. Waist circumference had the greatest clinical significance for UA level. Conclusions:The findings from our study suggest that metabolic syndrome risk factors do have a relationship with UA level, both in the total population and in those with metabolic syndrome. We found general trends that indicated that fasting blood glucose and HDL had negative relationships with UA level, whereas triglycerides, systolic BP, and waist circumference have positive relationships with UA. Diastolic BP did not demonstrate a relationship with UA level, and the relationship between HDL and UA was attenuated after adjustment for confounding variables. The findings suggest a need to further explore UA as a novel risk factor for metabolic syndrome.

show abstract

Predictive factors of hyperuricemia in diabetics Type 2: About 168 cases

Cited by 4 publications

References 0 publications

The association of serum uric acid level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status

The association of serum uric acid level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status

Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

Uric Acid as a Novel Component of Metabolic Syndrome

Contact Info

Product

Resources

About